Anebulo Pharmaceuticals, Inc.
General ticker "ANEB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $64.2M (TTM average)
Anebulo Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -36.6%.
Estimated limits based on current volatility of 19.8%: low 0.23$, high 0.34$
Factors to consider:
- Total employees count: 3 (0.0%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Operational and conduct risks, Future losses, Capital shortage, Regulatory and compliance, Clinical trial delays
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-06-30 to 2027-06-30
- 2025-06-30 to 2026-06-30 estimated range: [1.00$, 2.62$]
- 2026-06-30 to 2027-06-30 estimated range: [1.07$, 2.74$]
Financial Metrics affecting the ANEB estimates:
- Positive: with PPE of -5.8 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: Shareholder equity ratio, % of 95.98 > 64.23
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0.76 <= 3.34
Short-term ANEB quotes
Long-term ANEB plot with estimates
Financial data
| YTD | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $11.78MM | $8.31MM | $9.22MM |
| Operating Income | $-11.78MM | $-8.31MM | $-9.22MM |
| Non-Operating Income | $0.05MM | $0.11MM | $0.74MM |
| Interest Expense | $0.00MM | $0.15MM | $0.38MM |
| R&D Expense | $5.60MM | $3.55MM | $4.30MM |
| Income(Loss) | $-11.73MM | $-8.20MM | $-8.48MM |
| Net Income(Loss)* | $-11.73MM | $-8.20MM | $-8.48MM |
| Stockholders Equity | $10.60MM | $3.81MM | $11.66MM |
| Assets | $11.67MM | $4.07MM | $12.15MM |
| Operating Cash Flow | $-9.68MM | $-8.09MM | $-6.35MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $6.38MM | $-0.06MM | $14.88MM |
| Earnings Per Share** | $-0.47 | $-0.32 | $-0.25 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.